Marc K. Walton

2.3k total citations · 1 hit paper
25 papers, 1.4k citations indexed

About

Marc K. Walton is a scholar working on Economics and Econometrics, Statistics and Probability and Neurology. According to data from OpenAlex, Marc K. Walton has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Economics and Econometrics, 8 papers in Statistics and Probability and 5 papers in Neurology. Recurrent topics in Marc K. Walton's work include Health Systems, Economic Evaluations, Quality of Life (8 papers), Statistical Methods in Clinical Trials (8 papers) and Meta-analysis and systematic reviews (5 papers). Marc K. Walton is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (8 papers), Statistical Methods in Clinical Trials (8 papers) and Meta-analysis and systematic reviews (5 papers). Marc K. Walton collaborates with scholars based in United States, United Kingdom and Netherlands. Marc K. Walton's co-authors include Jürgen Schwarze, Stefan Unger, Clark D Russell, Jacquelyn A. Polder, Timothy R. Coté, Aparna Mohan, M. Miles Braun, Elizabeth Molsen, Spiros Vamvakas and Stefan Cano and has published in prestigious journals such as The Journal of Physiology, Clinical Microbiology Reviews and BMJ.

In The Last Decade

Marc K. Walton

24 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Human Immune Response to Respiratory Syncytial Virus Infection

2017 273 citations Marc K. Walton et al. profile →

Peers

Marc K. Walton

EPIDE

NEURO

SURGE

PRM

Charity Evans Canada

James Piercy United Kingdom

Raph Goldacre United Kingdom

Jonathan C. Hsu United States

Yinshan Zhao Canada

Elaine Kingwell Canada

Shelagh M. Szabo United States

Inge Christoffer Olsen Norway

De-min Han China

Koos Zwinderman Netherlands

Charity Evans Canada

Marc K. Walton

293 ×1.1

EPIDE

470 ×1.8

NEURO

124 ×0.8

SURGE

134 ×0.9

PRM

199 ×1.4

Citations per year, relative to Marc K. Walton Marc K. Walton (= 1×) peers Charity Evans

Countries citing papers authored by Marc K. Walton

Since Specialization

Citations

This map shows the geographic impact of Marc K. Walton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc K. Walton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc K. Walton more than expected).

Fields of papers citing papers by Marc K. Walton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc K. Walton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc K. Walton. The network helps show where Marc K. Walton may publish in the future.

Co-authorship network of co-authors of Marc K. Walton

This figure shows the co-authorship network connecting the top 25 collaborators of Marc K. Walton. A scholar is included among the top collaborators of Marc K. Walton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc K. Walton. Marc K. Walton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Polverejan, Elena, et al.. (2023). Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric Disorder. Therapeutic Innovation & Regulatory Science. 57(5). 911–939. 4 indexed citations

Moss, Jonathan, Luise A. Seeker, Marc K. Walton, et al.. (2022). Loss of the heterogeneous expression of flippase ATP11B leads to cerebral small vessel disease in a normotensive rat model. Acta Neuropathologica. 144(2). 283–303. 8 indexed citations

Dimairo, Munyaradzi, Philip Pallmann, James Wason, et al.. (2020). The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ. 369. m115–m115. 60 indexed citations

Walton, Marc K., Joseph C. Cappelleri, Bill Byrom, et al.. (2020). Considerations for development of an evidence dossier to support the use of mobile sensor technology for clinical outcome assessments in clinical trials. Contemporary Clinical Trials. 91. 105962–105962. 36 indexed citations

Perry, Brian, William G. Herrington, Jennifer C. Goldsack, et al.. (2018). Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010–2016: A Systematic Literature Review. PubMed. 2(1). 11–30. 56 indexed citations

Dimairo, Munyaradzi, Elizabeth Coates, Philip Pallmann, et al.. (2018). Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. BMC Medicine. 16(1). 210–210. 30 indexed citations

Powers, John H., Donald L. Patrick, Marc K. Walton, et al.. (2017). Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force. Value in Health. 20(1). 2–14. 106 indexed citations

Neal, Bruce, Vlado Perkovic, Kenneth W. Mahaffey, et al.. (2017). Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials. Diabetes Obesity and Metabolism. 19(7). 926–935. 79 indexed citations

Gallo, Paul, Weili He, Lisa A. Kammerman, et al.. (2016). DIA’s Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for “Less Well-understood” Adaptive Designs. Therapeutic Innovation & Regulatory Science. 51(1). 77–88. 7 indexed citations

10.

Paczesny, Sophie, Frances T. Hakim, Joseph Pidala, et al.. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: III. The 2014 Biomarker Working Group Report. PMC. 1 indexed citations

11.

Walton, Marc K., John H. Powers, Jeremy Hobart, et al.. (2015). Clinical Outcome Assessments: Conceptual Foundation—Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force. Value in Health. 18(6). 741–752. 180 indexed citations

12.

Paczesny, Sophie, Frances T. Hakim, Joseph Pidala, et al.. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biology of Blood and Marrow Transplantation. 21(5). 780–792. 98 indexed citations

13.

Cedarbaum, Jesse M., Diane Stephenson, Richard A. Rudick, et al.. (2014). Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology. Neurotherapeutics. 12(1). 151–169. 8 indexed citations

14.

Benedict, Ralph H. B. & Marc K. Walton. (2012). Evaluating cognitive outcome measures for MS clinical trials: what is a clinically meaningful change?. Multiple Sclerosis Journal. 18(12). 1673–1679. 28 indexed citations

15.

Woodcock, Janet, et al.. (2011). Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview. Expert Opinion on Medical Diagnostics. 5(5). 369–374. 17 indexed citations

16.

Bai, Jane P. F., Gilbert J. Burckart, Kenneth C. Fang, et al.. (2011). Translational Biomarkers: from Preclinical to Clinical a Report of 2009 AAPS/ACCP Biomarker Workshop. The AAPS Journal. 13(2). 274–283. 26 indexed citations

17.

Coté, Timothy R., Aparna Mohan, Jacquelyn A. Polder, Marc K. Walton, & M. Miles Braun. (2005). Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. Journal of the American Academy of Dermatology. 53(3). 407–415. 242 indexed citations

18.

Walton, Marc K.. (2004). Use of surrogate markers. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 5(sup1). 103–103. 1 indexed citations

19.

Nelson, Ralph, Anne E. Schaffner, Yongxin Li, & Marc K. Walton. (1999). Distribution of GABA_C-like responses among acutely dissociated rat retinal neurons. Visual Neuroscience. 16(1). 179–190. 9 indexed citations

20.

Schaffner, Anne E., et al.. (1998). Astrocytes regulate developmental changes in the chloride ion gradient of embryonic rat ventral spinal cord neurons in culture. The Journal of Physiology. 509(3). 847–858. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact